Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer s Association International Conference 2021
- Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer s disease
- Presentations include an assessment of the correlation between reductions in amyloid beta and other biomarkers of Alzheimer s disease and clinical decline after treatment with ADUHELM
- Presentation on ARIA data from Phase 3 trials provides insights for effective monitoring and management in real-world clinical practice
TOKYO, Jul 27, 2021 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer s disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELM (aducanumab-avwa) injection 100 mg/mL solution at the Alzheimer s Association International Conference